Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faster-acting Insulin Aspart in Cystic Fibrosis Related Diabetes
NCT04381429Phase 4Terminated
- Sponsor
- Strasbourg University Hospital
- Start
- Aug 2020
- Primary completion
- Jan 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of human insulin in cystic fibrosis-related diabetes (CFRD) (2 arms), sponsored by Strasbourg University Hospital. Primary endpoint: Change of time in range of blood glucose variation (70-180 mg/dl) at 12 months. Started Aug 2020; status: terminated.
02
Drugs
human insulin
03
Conditions
cystic fibrosis-related diabetes (CFRD)
Beyond the preview
Go deeper on NCT04381429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04381429.